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Aims The role of Ca2+ sensitization induced by a Ca2+-independent myosin light chain kinase (MLCK) in hypertension has
not been determined. The aim of this study was to clarify the role of possible Ca2+-independent MLCK activity in
hypertension.
Methods
and results
We compared increases in contractile force and phosphorylation of myosin light chain (MLC) evoked by calyculin A, a
phosphatase inhibitor, inb-escin-permeabilizedmesenteric arteries at pCa 9.0 between spontaneously hypertensive rat
(SHR) andWistar Kyoto rat (WKY).We found that therewas no detectable phosphorylation ofMLC at pCa 9.0, but that
the administration of 1 mM calyculin A gradually increased force and mono- and di-phosphorylation of MLC. This con-
traction was inhibited by staurosporine but not by wortmannin, Y-27632, or calphostin-C. The calyculin A-induced
contraction was significantly greater in the SHR than in the WKY and was associated with an increase in mono- and
di-phosphorylation of MLC. SM-1, a zipper-interacting protein kinase (ZIPK)-inhibiting peptide, significantly inhibited
the amplitude of the calyculin A-induced contraction and di-phosphorylation. Total ZIPK expression (54 + 32 kDa)
was greater in the SHR than in the WKY. Phosphorylation of myosin phosphatase target subunit at Thr697, but not at
Thr855, was consistently stronger in the SHR than in the WKY in calyculin A-treated tissues at pCa 9.0.
Conclusions Our results suggest that Ca2+-independent MLCK activity is enhanced in the SHR, and that ZIPK plays, at least in part,
an important role as a candidate for this kinase in rat mesenteric arteries.
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1. Introduction
Smooth muscle contraction is activated primarily by phosphorylation
at Ser19 of the 20 kDa regulatory light chains of myosin II (RLC20),
1
which is controlled by the opposing activities of myosin light chain
kinase (MLCK)2 and myosin light chain phosphatase (MLCP).3 The
amplitude of contraction can be affected by any change in the ratio
of MLCK:MLCP activity. MLCK activity is dependent on Ca2+-
calmodulin; hence, the intracellular Ca2+ concentration ([Ca2+]i) is
the primary determinant of smooth muscle contraction.4 However,
both contractile force development and RLC20 phosphorylation in
smooth muscle can be elicited without corresponding changes in
[Ca2+]i. The increase in sensitivity of smooth muscle contractile
response to [Ca2+]i (i.e. Ca
2+ sensitization) may be caused by inhi-
bition of MLCP activity4 or by activation of extracellular-regulated
kinase-mediated caldesmon phosphorylation.5 Inhibition of MLCP
can occur either directly by phosphorylation of the myosin phospha-
tase target subunit (MYPT1) of MLCP6 or indirectly via phosphoryl-
ation of a protein kinase C (PKC)-potentiated phosphatase inhibitor
protein of 17 kDa (CPI-17).7
Another possible mechanism for Ca2+ sensitization also exists.
Ca2+-independent MLCK activity has been identified. When
microcystin-LR, a type 1 and 2A phosphatase inhibitor, is applied to
permeabilized smooth muscle strips in Ca2+-free media, a Ca2+-
independent sustained contraction is observed, which cannot be
attributed to traditional MLCK activity.8–10 This Ca2+-independent
contraction is accompanied by di-phosphorylation of RLC20 at Ser
19
and Thr18.10 Similar results have been obtained with a number of
different smooth muscle tissues and with other type 1 and 2A phos-
phatase inhibitors, okadaic acid, and calyculin A,11–13 suggesting a
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common mechanism. Since MLCK is absolutely dependent on Ca2+
and, at physiological levels of the kinase, is specific for phosphorylation
at Ser19, the kinase responsible is clearly not MLCK itself.14 Previous
reports have suggested several candidates for this Ca2+-independent
MLCK, including rho-associated kinase (ROCK),15 PKC,16 mitogen-
activated protein kinase (MAPK)–activated protein kinase-2,17
MAPK-activated protein kinase-1b,18 Integrin-linked kinase (ILK),19
and ZIPK.8 Phosphorylation of RLC20 by ROCK, MAPK-activated
protein kinase-2, MAPK-activated protein kinase-1b is restricted to
Ser19, and PKC phosphorylates neither Ser19 nor Thr18. Furthermore,
among these kinases, only ROCK15, ILK19, and ZIPK8 have been
shown to induce RLC20 phosphorylation and contraction of smooth
muscle. Taken together, only ILK and/or ZIPK have emerged as practi-
cal candidates to fill the role of Ca2+-independent MLCK for the
di-phosphorylation of RLC20 and contraction of smooth muscle.
20
Earlier reports have shown that myosin in di-phosphorylated RLC20
has a higher actin-activated Mg2+-ATPase activity than mono-
phosphorylated RLC20
21,22, and di-phosphorylation of the RLC20 enhances
the tension acting on stress fibres in fibroblasts.23 While RLC20 mono-
phosphorylation is most commonly observed in smooth muscle tissue
in response tophysiological contractile stimuli, RLC20 di-phosphorylation
is more commonly observed in pathological situations such as vasos-
pasm.24,25 These observations have led to the suggestion that
di-phosphorylation of RLC20 is associated with hypercontractility of vas-
cular smooth muscle. Furthermore, augmented Ca2+ sensitization has
been reported in hypertensive animal models.26–28
Although pathological alterations to the sensitivity of the smooth
muscle contractile response to Ca2+ have been hypothesized to
underlie many diseases, such as hypertension29,30 and vasospasm,31
the role of Ca2+ sensitization induced by a Ca2+-independent MLCK
in hypertension has not been determined and the precise identity of
the Ca2+-independent MLCK remains controversial. In the present
study, we determined that an increased contractile force and
di-phosphorylation of RLC20 caused by a Ca
2+-independent MLCK
occurs in amodel of hypertension and, furthermore, that the subcellular
mechanism likely involves ZIPK-mediated phosphorylation of MYPT1.
2. Methods
This investigation confirms with the Guide for the Care and Use of Lab-
oratory Animals published by the US National Institutes of Health (NIH
publication No. 85-23, revised 1996). All procedures were performed
in accordance with protocols approved by the Institutional Animal Care
and Use Committee of Yonsei University College of Medicine.
2.1 Tissue preparation and organ bath study
Male spontaneously hypertensive rat (SHR) and Wistar Kyoto rat (WKY)
aged 16–18 weeks were purchased from Japan SLC, Inc., Inasa Production
Facility. The mean systolic blood pressures of the SHR and WKY rats
measured by the tail-cuff method were 202+10 and 145+
10.5 mmHg, respectively.
The rats were killed by decapitation. All mesenteric arteries were
excised and placed in a HEPES-Tyrode solution composed of the follow-
ing (in mmol/L): NaCl, 134; KCl, 5.6; CaCl2, 2.5; MgCl2, 1; HEPES, 10;
glucose, 10. The HEPES-Tyrode solution was continuously aerated with
100% O2. The second or third branches of the mesenteric arteries
were dissected and ring segments (1 mm in length) were prepared.
Fat and adventitia were removed mechanically under a binocular micro-
scope, and the endothelium of the arterial ring was removed by gently
rubbing the endothelial surface with the edge of a forceps. Removal of
endothelium was confirmed by observing the absence of relaxation on
challenge with acetylcholine when 70 mmol K+ solution (equimolar sub-
stitution of Na+ with K+)-induced contraction had reached a plateau.
Force was measured as we have previously described.32
2.2 Permeabilization with b-escin and force
recording
Force in permeabilized preparations was measured as we have previously
described.32,33 Briefly, 1 mM calyculin A and several inhibitors were
treated after stable responses were obtained at pCa 9.0. All experiments,
except the experiments concerned with the effect of several protein
kinase inhibitors and SM-1 peptide on calyculin A-induced contraction,
were conducted in 10 mM wortmannin (inhibitor of Ca2+-dependent
MLCK and phosphatidylinositol 3-kinase)-treated tissues to eliminate
the possible contribution of Ca2+-dependent MLCK.
2.3 RLC20 phosphorylation measurements
Phosphorylation of the RLC20 in the SHR and WKY was measured using
glycerol-urea minigels as described previously.34 The vessels were frozen
when the contractile response became stable at pCa 9.0, pCa 4.5, and pCa
9.0 with calyculin A.
2.4 Sodium dodecyl sulfate polyacrylamide gel
electrophoresis and western blotting
The expression levels of proteins in non-stretched SHR and WKY mesen-
teric arteries, the effects of calyculin A on the mono- and
di-phosphorylation of the RLC20, Thr
697, and Thr855 phosphorylation of
MYPT1, and CPI-17 phosphorylation were measured by using western
blot as described previously.32
2.5 Immunofluorescence
The expression of protein in the first or second mesenteric branches and
di-phosphorylated forms of RLC20 in the SHR and WKY were measured
by the immunofluorescence method using a confocal laser scanning
microscope. Non-stretched arteries and vessels after a functional study
were fixed with paraformaldehyde embedded in an optimal cutting temp-
erature (Sakura Fine Tec Inc., Torrance, CA, USA) compound and frozen
in liquid nitrogen. The frozen sections (10 mm) were cut onto gelatin-
coated slides, air-dried, and then washed with phosphate-buffered saline
(PBS; 137 mmol/L NaCl, 2.7 mmol/L KCl, 10.14 mmol/L Na2HPO4,
1.76 mmol/L KH2PO4, 0.05% Tween 20). After a blockade with blocking
solution composed of PBS containing 3% bovine serum albumin and
0.5% Triton X-100, the sections were incubated with primary antibodies
in blocking solution overnight in a humidified chamber at room tempera-
ture. The specific primary antibodies used are as follows: ZIPK (1:50, Santa
Cruz), total MLC (1:100, Sigma), b-actin (1:500, Abcam), and ppMLC
(1:100, Cell Signaling, MA, USA). After washing with PBS, sections were
incubated with the secondary antibodies for 1 h in the dark. Immunofluor-
escent signals were viewed using a confocal laser scanning microscope
(Carl Zeiss, LSM 510) with oil immersion lens.
The specificity of the immunostaining was evaluated by omission of the
primary antibody (negative control) and processed as above.
2.6 Drugs
The following drugs were used: calyculin A (Enzo Life Science;
Farmingdale, NY, USA), wortmannin (Enzo Life Science), trans-4-[(1R)-
1-Aminoethyl]-N-4-pyridinylcyclohexanecarboxamide (Y-27632; Enzo
Life Science), calphostin-C (Sigma), staurosporine (Sigma), SM-1
peptide (sequence: AKKLSKDRMKKYMARRKWQKTG, Bio Basic Inc.
and Thermo scientific), and scramble SM-1 peptide (sequence:
KWARMKDKAMRYKTKGRLQKSK, Bio Basic Inc. and Thermo scientific).
The general laboratory reagents used were analytical grade or better.
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2.7 Statistics
All values given in the text are expressed as mean+ SEM and were ana-
lysed by ANOVA, followed by Tukey’s test. Significant differences were
taken at the P, 0.05 level. Force was expressed as a relative percentage
of the amplitude of the contraction at pCa 4.5.
3. Results
3.1 Calyculin A induces a
Ca21-independent contraction
of b-escin-permeabilized rat mesenteric
arterial smooth muscle
Figure 1A depicts a typical calyculin A-induced contraction of b-escin-
permeabilized rat mesenteric arterial smooth muscle in the absence
of Ca2+. b-escin-permeabilized tissue contracted in response to an
increase in [Ca2+] (pCa 4.5) and relaxed upon return to pCa 9.0.
The administration of 1 mM calyculin A to the permeabilized
smooth muscle in pCa 9.0 elicited a gradual increase in force, reaching
a plateau 20–30 min after administration (Figure 1A). To clarify which
kinase is responsible for the calyculin A-induced Ca2+-independent
contraction, we examined the effects of various protein kinase inhibi-
tors on the calyculin A-induced contraction at pCa 9.0 (Figure 1B–F ).
The compounds evaluated included inhibitors of: MLCK (1025 M
wortmannin), ROCK (1025 M Y-27632), PKC (5 × 1027M
calphostin-C), and a non-specific, broad-spectrum protein kinase
inhibitor (1025 M staurosporine). As shown in Figure 1, wortmannin,
Y-27632, and calphostin-C were ineffective, whereas staurosporine
inhibited the calyculin A-induced contraction. Staurosporine
decreased the calyculin A-induced contraction from 59.9+5.2% (n
¼ 7, contraction normalized to maximal pCa 4.5-induced contraction)
to 6.7+ 6.7% (n ¼ 4, P, 0.01).
Figure 1 Characterization of protein phosphatase inhibitor, calyculin A-induced contraction in b-escin-permeabilized rat mesenteric arterial
smooth muscle. (A) Typical recording for the effect of 1 mM calyculin A in b-escin-permeabilized rat mesenteric arteries at pCa 9.0. (B–E) Typical
recording for the effects of protein kinase inhibitors on the calyculin A-induced contraction at pCa 9.0. 1025 M staurosporine (B), 1025 M wortmannin
(C), 1025 M Y-27632 (D), and 5 × 1027 M calphostin-C (E) were applied 15 min before administration of calyculin A. (F) Mean data for calyculin
A-induced contraction with protein kinase inhibitors at pCa 9.0. The magnitude of contraction was normalized by the response of pCa 4.5
(100%). Data are a summary of 4–15 independent experiments and are expressed as mean+ SEM. *, P, 0.01. (G) Control data for Ca2+ (pCa
4.5)-induced contraction.
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3.2 The Ca21-independent, calyculin
A-induced contraction and RLC20
phosphorylation are augmented in the SHR
To clarify whether the Ca2+-independent, calyculin A-induced con-
traction increases in a hypertensive model, we compared the caly-
culin A-induced contraction in permeabilized rat mesenteric arterial
smooth muscle of SHR and WKY at pCa 9.0. As shown in
Figure 2A, the Ca2+-independent, calyculin A-induced contraction
was concentration dependent. The maximum response was
obtained at 1 mM in the SHR and the WKY, but the amplitude
of the contraction was greater in the SHR (79.0+ 7.8%, n ¼ 9)
than in the WKY (53.6+4.1%, n ¼ 7; Figure 2A). We further com-
pared the effect of calyculin A on RLC20 phosphorylation in the
permeabilized rat mesenteric arterial smooth muscle of SHR and
WKY. We first examined the level of RLC20 phosphorylation
with a total RLC20 antibody using urea/glycerol gel electrophoresis
that separates un-phosphorylated and phosphorylated forms of
RLC20. As shown in Figure 2B, in permeabilized tissue, during appli-
cation of pCa 4.5, un- and mono-phosphorylated forms of RLC20
were detected in both SHR and WKY tissues, but the signal for
mono-phosphorylated forms of RLC20 was stronger in the SHR
than in the WKY. Di-phosphorylated forms of RLC20 were not
detected in pCa 4.5. In the case of pCa 9.0 without calyculin A,
the total RLC20 antibody recognized only un-phosphorylated
forms of RLC20 in control SHR and WKY tissues. However, in
the presence of calyculin A at pCa 9.0, three bands, un-, mono-,
and di-phosphorylated forms of RLC20 appeared in both SHR
and WKY. The amounts of mono- and di-phosphorylated RLC20
were larger in the SHR than in the WKY.
We also compared agonist-induced di-phosphorylation in intact
arterial smooth muscle of SHR and WKY to clarify if the agonist
can induce di-phosphorylation and whether agonist-induced
di-phosphorylation is augmented in a hypertensive animal model. As
shown in Figure 2C, phenylephrine-induced di-phosphorylation of
RLC20 and di-phosphorylated forms of RLC20 were augmented in
the SHR compared with the WKY in intact tissue. We also compared
the levels of RLC20 mono- and di-phosphorylation induced by Ca
2+-
independent, calyculin A in permeabilized rat mesenteric arterial
smooth muscle of SHR and WKY using sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS/PAGE) with antibodies specific
for RLC20 phosphorylated exclusively at Ser
19 or both Ser19 and
Thr18. As shown in Figure 3, the results obtained are similar to
those seen with urea/glycerol gel electrophoresis. In SHR and WKY,
Ser19-phosphorylated RLC20 (Figure 3A) was increased in pCa 4.5
alone and in pCa 9.0 with calyculin A, but Ser19- and Thr18-
Figure 2 Changes in Ca2+-independent, calyculin A-induced contractions and RLC20 phosphorylation between SHR and WKY. (A) Concentration-
dependent effect of Calyculin A in b-escin-permeabilized mesenteric arteries of SHR (n ¼ 9) and WKY (n ¼ 7) at pCa 9.0. *, P, 0.01. (B1–B3) After
b-escin permeabilization, RLC20 phosphorylation levels at various conditions. These results are representative of four independent experiments. The
vessels are collected at peak contraction induced by pCa 4.5 (1), at pCa 9.0 without calyculin A (2), and at peak contraction induced by 1 mM calyculin
A at pCa 9.0 (3). Un- (P0), mono- (P1), and di-(P2) phosphorylated forms of RLC20 were separated by urea/glycerol gel electrophoresis. The densito-
metric sum of the bands in each category was normalized to that seen in the WKY (B3). (C) Effect of phenylephrine on RLC20 di-phosphorylation in
intact arteries of WKY and SHR. **, P, 0.05. WKY, Wistar Kyoto rat; SHR, spontaneously hypertensive rat; CAL-A, calyculin A.
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di-phosphorylated RLC20 (Figure 3B) was increased only in pCa 9.0
with calyculin A. Quantification of the immunoblots shows that Ser19-
phosphorylated RLC20 at pCa 4.5 and at pCa 9.0 with calyculin A are
stronger in the SHR than in protein-matched samples from the WKY.
However, Ser19- and Thr18- di-phosphorylated forms of RLC20 are
stronger in the SHR than in protein-matched samples from the
WKY only at pCa 9.0 with calyculin A, but not with pCa 4.5 alone.
Finally, we confirmed the expression levels of di-phosphorylated
forms of RLC20 using immunostaining and image analysis with confocal
microscopy. As shown in Figure 3C, in SHR and WKY,
di-phosphorylated RLC20 was not detected at pCa 9.0, whereas
di-phosphorylated RLC20 was significantly increased at pCa 9.0 with
calyculin A. These results indicate that the contraction induced by
calyculin A at pCa 9.0 was accompanied by an increase in mono-
and di-phosphorylation of RLC20.
3.3 Identification of the protein kinase
involved in the Ca21-independent,
calyculin A-induced contraction
To identify the nature of protein kinase involved in Ca2+-independent,
calyculin A-induced contraction and RLC20 di-phosphorylation, we
studied the effects of SM-1, a ZIPK-inhibiting peptide, on the calyculin
A-induced contraction and di-phosphorylation of RLC20 in permeabi-
lized rat mesenteric arterial smooth muscle. As shown in Figure 4A,
SM-1 (100 mM) significantly inhibited the amplitude of contraction
(31.1+9.3%, n ¼ 5) induced by calyculin A at pCa 9.0 (Figure 4A2)
compared with the control group (57.9+ 3.6%, n ¼ 9; Figure 4A1),
but scrambled SM-1 had no effect on the calyculin A-induced contrac-
tion (57.4+7.4%, n ¼ 3; Figure 4A3). SM-1 also significantly inhibited
the amount of di-phosphorylation induced by calyculin A (Figure 4B).
To confirm the presence of ZIPK in mesenteric arterial smooth
muscle, we studied the double immunofluorescence staining of
ZIPK and actin or myosin light chain (MLC) in rat mesenteric arterial
smooth muscle. As shown in Figure 4C, ZIPK immunoreactivity was
verified by co-staining with smooth muscle-specific actin or MLC
(Figure 4C). The negative control obtained without primary antibodies
gave no detectable signal. To determine whether expression of ZIPK
changes in SHR animals, we measured the expression of ZIPK in the
rat mesenteric artery of SHR and WKY using western blot. We also
compared the expression levels of ROCK, CPI-17, and ILK. As shown
in Figure 4D, anti-ZIPK detected a prominent band of both 32 kDa and
54 kDa in SHR and a weaker band in protein-matched WKY tissues.
Quantification of the immunoblots showed that total (54 + 32 kDa)
ZIPK is 1.3+0.04-fold (n ¼ 23) more abundant in the SHR than in
protein-matched samples from the WKY. ROCK (180 kDa) was
detected in both SHR and WKY tissues, and the signal was consist-
ently stronger in the SHR than in the WKY. CPI-17 and ILK were
detected in both SHR and WKY tissues at equal expression levels.
3.4 Contribution of MYPT1 and CPI-17
phosphorylation to MLCP inhibition
during calyculin A-induced contraction
in SHR and WKY
We examined whether calyculin A modifies phosphorylation of
specific sites on MYPT1 and whether differences in MYPT1 phos-
phorylation induced by calyculin A exist between SHR and WKY.
As shown in Figure 5A, Thr697 (numbering for rat isoform) phos-
phorylation of MYPT1 was significantly increased by treatment of
SHR and WKY tissue with calyculin A at pCa 9.0 compared with
pCa 9.0 alone, and the signal was consistently stronger in the SHR
than in the WKY. Quantification of immunoblots for calyculin A
Figure 3 RLC20 phosphorylation at Ser
19 and Thr18 is increased in the SHR. (A and B) Ser19-(pMLC) and both Ser19 and Thr18 phosphorylated
(ppMLC) RLC20 levels in SHR and WKY at pCa 9.0, pCa 4.5, and pCa 9.0 with calyculin A using SDS/PAGE gel electrophoresis with antibodies specific
for RLC20 phosphorylated exclusively at Ser
19 (A) or both Ser19 and Thr18 (B). The magnitude of phosphorylation was expressed as a pMLC/actin
(lower panel of A) or ppMLC/actin (lower panel of B). *, P, 0.01; **, P, 0.05 (n ¼ 7). (C) Immunofluorescence staining for di-phosphorylated
forms (ppMLC) of RLC20. Data were obtained with confocal microscopy. Scale bar: 50 mm.
Y.-E. Cho et al.166
and pCa 9.0 gave a Thr697 phosphorylation/total MYPT1 ratio of
1.68+ 0.3 (n ¼ 7) in SHR and 1.06+0.1 (n ¼ 7) in WKY. Thr855
(numbering for rat isoform) phosphorylation of MYPT1 was signifi-
cantly increased by treatment of SHR and WKY tissue with calyculin
A in addition to pCa 9.0 conditions, but the phosphorylation levels
increased by calyculin A did not differ significantly between SHR
and WKY (Figure 5B).
We also examined the possibility that calyculin A-induced contrac-
tions could be a reflection of the CPI-17 phosphorylation status.
However, as shown in Figure 5C, phosphorylation levels of CPI-17
increased by calyculin A were not significantly different between
SHR and WKY.
4. Discussion
The present study demonstrates that, in a model of hypertension,
there is a significant increase in Ca2+-independent, calyculin
A-induced contractions. This type of contraction is significantly
greater in the SHR than in the WKY, and the augmentation of con-
tractions in the SHR is associated with an increase in mono- and
di-phosphorylation of RLC20. We also show that ZIPK appears to
be the Ca2+-independent MLCK involved. We provide evidence
that SM-1, a ZIPK-inhibiting peptide, significantly inhibits the contrac-
tion and di-phosphorylation of RLC20 induced by calyculin A at pCa
9.0, that ZIPK is expressed in the mesenteric artery, and that the
expression level of ZIPK is higher in the SHR than in the WKY.
Finally, we show that the increase in Thr697 phosphorylation of
MYPT1, likely caused by the higher expression levels of ZIPK in
SHR, plays an important role in the enhanced calyculin A-induced
contraction and RLC20 phosphorylation in SHR. Taken together,
these results suggest that Ca2+-independent MLCK activity is
enhanced in the SHR and that the increase in the expression level
of ZIPK in SHR appears to play an important role in the enhanced
calyculin A-induced contraction and RLC20 phosphorylation.
To investigate the existence of Ca2+-independent contraction and
di-phosphorylation of RLC20 in rat mesenteric arterial smooth muscle,
we first measured the effects of calyculin A on the contractility of
b-escin-permeabilized arterial smooth muscle at pCa 9.0. MLCK is
absolutely dependent on Ca2+ and calmodulin for its activity, and
has no activity under these experimental conditions. Thus, in the
absence of Ca2+ (pCa 9.0), we found that there is no phosphorylation
of MLC in this system (Figure 2). However, we also showed that
Figure 4 Effect of SM-1 on Ca2+-independent, calyculin A-induced contraction and expression of various protein kinases in SHR and WKY.
(A) Effect of SM-1 on Ca2+-independent, calyculin A-induced contraction of b-escin-permeabilized rat mesenteric arteries. Contraction induced
by 1 mM calyculin A in the absence of peptide (A1) and in the presence of 100 mM SM-1 (A2) or scrambled SM-1 (scSM-1, A3). (A4) Mean data for
the effect of SM-1 (or scSM-1) on calyculin A-induced contraction at pCa 9.0. The magnitude of the contraction was normalized by the response
of pCa 4.5 (100%). **, P, 0.05 (n ¼ 3–9). (B) Effect of SM-1 on calyculin A-induced di-phosphorylation of b-escin-permeabilized rat mesenteric
arteries. (C) Double immunofluorescence staining for ZIPK and actin or myosin light chain (MLC) in rat mesenteric arterial smooth muscle. Local-
ization of ZIPK immunoreactivity (C1 and C7), actin (C2), or MLC (C8), and (C3 and C9) their co-localization in smooth muscle tissues. C4–6 and C10–12.
The negative controls consisted of omission of the primary antibody. Scale bar: 50 mm. (D1) Immunoblots of ROCK, CPI-17, ILK, and ZIPK in rat
mesenteric arteries of SHR and WKY. (D2) The magnitude of expression was expressed as a SHR/WKY ratio. **. P, 0.05 (n ¼ 12–23).
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calyculin A induces a gradual increase in force and mono- and
di-phosphorylation of RLC20 in permeabilized rat mesenteric arterial
smooth muscle at pCa 9.0. We also showed that the calyculin
A-induced contraction is insensitive to treatment with wortmannin,
Y-27632, and calphostin-C, ruling out the involvement of traditional
MLCK, ROCK, or PKC in this Ca2+-independent contraction. These
results are consistent with previous reports8,11–13,35 and suggest
that a Ca2+-independent MLCK activity is unmasked in our exper-
imental conditions.
To clarify whether the Ca2+-independent MLCK activity might be
increased in hypertension, we used a model of hypertension, the
SHR, and compared Ca2+-independent, calyculin A-induced contrac-
tions in permeabilized rat mesenteric arterial smooth muscle of SHR
and WKY at pCa 9.0. We showed that the amplitude of calyculin
A-induced contraction is greater in the SHR than in the WKY. Con-
sistent with this finding, we also showed that in the presence of caly-
culin A at pCa 9.0, the prevalence of mono- and di-phosphorylated
forms of RLC20 is stronger in SHR than in WKY. In the present
study, we measured RLC20 phosphorylation using three different
methods: urea/glycerol gel electrophoresis with a total RLC20 anti-
body, SDS/PAGE gel electrophoresis with antibodies specific for
RLC20 phosphorylated exclusively at Ser
19 or both Ser19 and Thr18,
and immunostaining and image analysis with confocal microscopy.
Consistent results were obtained with all three methods, and the
results indicate that an increase in the amplitude of calyculin
A-induced contraction in the SHR is associated with elevations in
the mono- and di-phosphorylated forms of RLC20.
It is well known that phosphorylation of RLC20 at Ser
19 markedly
increases actin-activated Mg2+-ATPase activity of smooth muscle
myosin,36 and this is known to be further enhanced by additional
phosphorylation at Thr18.21 In vascular smooth muscle tissues,
RLC20 di-phosphorylation has been observed in pathological con-
ditions such as vasospasm.24,25 In addition, we previously reported
that the [Ca2+]i-induced contraction is larger in SHR than in WKY,
and the [Ca2+]i-force curve is significantly shifted to the left in SHR
when compared with WKY.33 These observations have led to the sug-
gestion that di-phosphorylation of RLC20 is associated with hypercon-
tractility in vascular smooth muscle. Our results indicate that Ca2+
sensitization by Ca2+-independent MLCK activity might play an
important role in the hypercontractility of vascular smooth muscle
of SHR.
Since Ca2+-independent, microcystin-LR-induced contraction and
RLC20 phosphorylation were first demonstrated by Kureishi et al.
35
a number of different Ca2+-independent kinases have subsequently
been shown to phosphorylate RLC20 in vitro.
20 However, ILK and
ZIPK have emerged as the most likely candidates for Ca2+-
independent di-phosphorylation of RLC20 at Ser
19 and Thr18 in
smooth muscle.20 In the present study, to identify the nature of the
protein kinase causing the Ca2+-independent, calyculin A-induced
contraction and RLC20 di-phosphorylation, we studied the effects of
SM-1, a ZIPK-inhibiting peptide, on the calyculin A-induced contrac-
tion and di-phosphorylation of RLC20. SM-1 significantly inhibited
the amplitude of contraction and di-phosphorylation of RLC20
induced by calyculin A at pCa 9.0; in contrast, scrambled SM-1 had
no effect. We also showed that ZIPK is expressed in the rat mesen-
teric artery, in both the 32 kDa and 54 kDa forms of ZIPK, and that
more ZIPK is present in the SHR than in the WKY. It has been
shown that a 32 kDa form of ZIPK, expressed in the smooth
muscle, co-localizes with actin filaments and plays a role in the regu-
lation of smooth muscle contraction.37 A 54 kDa form of ZIPK is also
expressed in smooth muscle and activated by prostaglandin F2a
stimulation.38 Taken together, our results suggest that the increased
expression levels of ZIPK in SHR induce augmentation of the calyculin
A-induced contraction and RLC20 phosphorylation. However, in the
present study, calyculin A-induced residual contraction in the pres-
ence of SM-1, a ZIPK-inhibiting peptide, still exists despite the fact
that we used the concentration of SM-1 which is the maximal effective
dose. Therefore, ILK might be another possible candidate for Ca2+-
independent MLCK, although it was detected at equal expression
levels in both SHR and WKY tissues in the present study.
Figure 5 Analysis of MYPT1 and CPI-17 phosphorylation contribution to Ca2+-independent, calyculin A-induced contraction in SHR and WKY.
(A andB) Changes of Thr697 (A) and Thr855 (B) phosphorylation of MYPT1 by treatment of calyculin A at pCa 9.0 (CAL-A/pCa 9.0) in b-escin-
permeabilized rat mesenteric arteries of SHR and WKY. (C) Changes of phosphorylation of CPI-17 by treatment of calyculin A at pCa 9.0
(CAL-A/pCa 9.0) in b-escin-permeabilized rat mesenteric arteries of SHR and WKY. Data are expressed as signal-intensity ratios for phosphorylated
(pThr697 and pThr855 or pCPI-17): total (Total MYPT1 or Total CPI-17) MYPT1 or CPI-17. *, P, 0.01 (n ¼ 7).
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We found the expression level of ROCK to be stronger in the SHR
than in the WKY. Because ROCK can activate ZIPK, ROCK also
plays an important role for Ca2+-independent MLC phosphorylation.
However, because the ROCK inhibitor Y-27632 had no inhibitory
effect on the calyculin A-induced contraction, ROCK might not be
a candidate for the Ca2+-independent MLCK.
Interestingly, we also found evidence for an effect of ZIPK to phos-
phorylate MLCP in addition to its apparent direct effect to phosphor-
ylate RLC20. It is known that ZIPK can mediate inhibition of MLCP
39,40
either directly, via phosphorylation of the MYPT1, or indirectly, via
phosphorylation of a CPI-17.41 Therefore, augmentation of
di-phosphorylation by calyculin A in the SHR may be due to inhibition
of MLCP, either directly, through enhanced phosphorylation of the
MYPT1 of MLCP, or indirectly, through enhanced phosphorylation
of a CPI-17. To clarify this possibility, we examined the differences
of MYPT1 phosphorylation induced by calyculin A between SHR
and WKY. We showed that both Thr697 and Thr855 phosphorylation
of MYPT1 was significantly increased by the treatment of SHR and
WKY tissue with calyculin A at pCa 9.0, but the signal of phosphoryl-
ation at Thr697, and not at Thr855, was consistently stronger in the
SHR than in the WKY. These results are consistent with the previous
finding that ZIPK directly regulates MYPT activity through phosphoryl-
ation of Thr696 (numbering for human isoform and equivalent to
Thr697).42 We also showed that the phosphorylation of CPI-17 was
significantly increased by treatment of SHR and WKY tissue with caly-
culin A at pCa 9.0, and that the increase caused by calyculin A was
similar in both SHR and WKY. Taken together, our results suggest
that the increase in both Thr697 phosphorylation of MYPT1 and
direct phosphorylation of RLC20, driven by the higher expression
levels of ZIPK in SHR, plays an important role in the enhanced caly-
culin A-induced contraction and RLC20 phosphorylation in this
model of hypertension.
In the present study, the SHR have been employed as animal
models of human primary (essential) hypertension. Although SHR
are widely used as a model to investigate the mechanisms underlying
essential hypertension, there are some differences between SHR and
human hypertension. Therefore, further study is needed to elucidate
the role of Ca2+ sensitization induced by Ca2+-independent MLCK in
hypertension using other hypertensive animal models, such as deox-
ycorticosterone acetate salt-induced hypertensive rats. Investigation
is also necessary into whether the increased contractility and
di-phosphorylation of RLC20 induced by Ca
2+-independent MLCK
in hypertension is a causative factor or a consequence of hypertension
development.
In summary, our results suggest that contraction and phosphoryl-
ation of RLC20 induced by Ca
2+-independent MLCK activity are
further enhanced in the SHR than in the WKY, and ZIPK is a key can-
didate for causing this effect. Furthermore, the increase in the
expression level of ZIPK in SHR appears to play an important role
in enhanced calyculin A-induced contraction and RLC20
phosphorylation.
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